September 11th 2024
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Lung Cancer Tumor Board: Enhancing Precision Medicine in NSCLC Through Advancements in Molecular Testing and Optimal Therapy Selection
View More
Virtual Show Me the Data™: How HER2, HER3, and TROP2 Targeted Strategies Will Impact Evolving Paradigms in NSCLC
View More
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
19th Annual New York Lung Cancers Symposium®
November 16, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Identifying Actionable Biomarkers in NSCLC: Real World Case Discussions on Applications of Testing in the Treatment Planning Process
View More
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Lung Cancer Tumor Board®: Enhancing Multidisciplinary Communication to Optimize Immunotherapy in Stage I-III NSCLC
View More
Matching Treatment to Patient with EGFR-Mutant Lung Cancer: Mutation Subtypes, Co-Mutations, and Managing Resistance
View More
Improving Outcomes Across Frontline and R/R SCLC Care in Community Treatment Settings
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
18th Annual New York Lung Cancers Symposium®
View More
22nd Annual Winter Lung Cancer Conference®
January 31, 2025 - February 2, 2025
Register Now!
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
21st Annual Winter Lung Cancer Conference® In Line Session: Advent of TROP2-Directed ADCs In Lung Cancer
View More
LIVE! Testing Board®: Breaking Down Pathologic Reports to Identify Actionable Markers in Patients with NSCLC
View More
Tissue Stewardship and the Evolving Role of Genomic Alterations in Providing Precision NSCLC Care
View More
Community Practice Connection™: 21st Annual Winter Lung Cancer Conference®
View More
Revolutionizing Early-Stage NSCLC Treatment: Pathologists’ Key Insights Into Predicting Pathologic Responses to Immunotherapies
View More
BURST CME™: How Are Emerging Biomarkers and Testing Methodologies Shaping Personalized Medicine in NSCLC?
View More
Navigating Current State-of-the Art NSCLC Patient Care From the Front Lines: Essentials for Oncology Nurses Today and Tomorrow
View More
Medical Crossfire®: How Can Thoracic Teams Facilitate Optimized Care of Patients With Stage I-III EGFR Mutation-Positive NSCLC?
View More
Lung Cancer Tumor Board®: How Do Emerging Data for ICIs, BiTEs, ADCs, and Targeted Strategies Address Unmet Needs in the Therapeutic Continuum for SCLC?
View More
DLL3 as a Therapeutic Target in SCLC and Beyond: Rationale, Recent Data and Potential for Transformations in Care with T-Cell Engagers
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Top 10 Oncogenic Drivers in NSCLC for 2024: Where Are We and Where Are We Going?
View More
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
LUNGevity's 'Breathe Deep TOGETHER' Campaign Brings Awareness to Lung Cancer Misconceptions
August 13th 2024One of the biggest misconceptions about lung cancer is that it only affects smokers, according to Amy Moore, vice president of Global Engagement and Research Partnerships at LUNGevity.
Read More
Digital Tools Utilizing Patient Health Records Improve Lung Cancer Screening Rates
July 4th 2024Researchers from the University of Utah in Salt Lake City have developed a more comprehensive, multifaceted digital tool for lung cancer screening that integrates into EHR as well as patient portals. Their paper was published in JAMA Network Open in June 2024.
Read More
Exploring the Relationship Between Immunotherapy and Body Composition in Advanced NSCLC
June 10th 2024Researchers evaluated the association between body composition from readouts generated by cross-sectional imaging and oncologic outcomes in patients with advanced or metastatic NSCLC treated with systemic immunotherapy.
Read More
Two Opdivo Updates from Bristol Myers Squibb
May 14th 2024First approved by the U.S. Food and Drug Administration (FDA) in 2014, Opdivo has multiple indications across various types of cancer, including NSCLC, melanoma, renal cell carcinoma, Hodgkin lymphoma, squamous cell carcinoma of the head and neck, and urothelial carcinoma.
Read More
Study Suggests Role of Immunogenetic Associations in Lung Cancer Risk
March 7th 2024In the U.S., nearly 200,000 new cases of lung cancer were reported in 2020, with over 100,000 deaths. While the number of lung cancer deaths has generally decreased over the past 20 years, lung cancer remains the leading cause of cancer deaths in the US and is the third most common type of cancer.
Read More
Study: Long-Term Smoking Cessation Linked to Lower Cancer Risk, Even with Relapses
February 6th 2024It is well-known that smoking is linked to a higher risk of cancer, and those who smoke can lower their risk by quitting. However, it remains unclear exactly how many years of continued smoking cessation are needed to see a substantial risk reduction.
Read More
Trodelvy Falls Short As NSCLC Treatment, Taking Some of the Shine Off Antibody-Drug Conjugates
January 23rd 2024Gilead's share price fell 10% today after it announced that Trodelvy, an antibody-drug conjugate, failed to meet its overall survival end point in a trial testing it as treatment for metatstatic non-small cell lung cancer.
Read More
Liquid Biopsy May Guide Treatment and Improve Outcomes in Lung Cancer, New Study Shows
January 8th 2024While tissue biopsy is currently recommended as the gold standard for determining mutations in non-small cell lung cancer, its success is not guaranteed, prompting the consideration of the liquid biopsy method as a viable alternative.
Read More